- In November 2020, Alnylam has announced that the U.S. Food and Drug Administration (FDA) has approved OXLUMO (lumasiran), making it the first and only treatment authorized for Primary Hyperoxaluria Type 1 to reduce urinary oxalate levels in both pediatric and adult patients
